Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03461952
Title Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe)
Acronym NIMBLe
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Columbia University Medical Center New York New York 10032 United States Details
Tom Baker Cancer Centre Calgary Alberta T2N 4N2 Canada Details
BCCA - Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
Juravinski Cancer Centre at Hamilton Health Sciences Hamilton Ontario L8V 5C2 Canada Details
Ottawa Hospital Research Institute Ottawa Ontario K1H 8L6 Canada Details
University Health Network Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field